# A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)

> **NCT00109109** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 60 (—)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months

## Key facts

- **NCT ID:** NCT00109109
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12-01
- **Primary completion:** 2006-02-14
- **Final completion:** 2006-02-14
- **Target enrollment:** 60 (—)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109109, "A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00109109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*